Comparison
AOD-9604 vs Fisetin
Side-by-side of AOD-9604 and Fisetin. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
AOD-9604
AOD 9604 peptide: 16-amino-acid hGH fragment 176-191. Preclinical lipolytic activity, phase 2 obesity trial showed no weight loss vs placebo.
Fisetin
Fisetin is a flavonoid found in strawberries with senolytic activity in mouse models. Hickson 2019 confirmed senescent-cell clearance in human adipose tissue.
Effects at a glance
AOD-9604
- •Modified 16-amino-acid synthetic fragment of human growth hormone (residues 176-191)
- •Preclinical models show lipolytic activity in adipose tissue without GH-axis growth effects
- •Phase 2 obesity trial (Heffernan 2001) showed no significant weight-loss difference versus placebo
- •Anecdotal protocols use 250 to 500 mcg subcutaneously daily on an empty stomach
- •No FDA approval; the obesity drug development program was discontinued in 2007
- •Granted GRAS status in some jurisdictions for compounded use; not validated for fat loss in humans
Fisetin
- •Flavonoid found in strawberries; most potent natural senolytic in screening assays (Yousefzadeh 2018)
- •Hickson 2019 confirmed reduced senescent-cell burden in human adipose tissue at 20 mg/kg pulsed for 2 days
- •Pulsed Mayo protocol (20 mg/kg/day x 2 days monthly) is the only dose with human biomarker evidence
- •Daily low-dose (100-500 mg) is mechanistically weaker but commonly used
- •Low oral bioavailability; with-fat dosing modestly improves absorption
- •Active cancer is a relative contraindication pending clearer polyphenol-treatment data
Side-by-side
| Attribute | AOD-9604 | Fisetin |
|---|---|---|
| Category | peptide | supplement |
| Also known as | hGH fragment 176-191, Human Growth Hormone Fragment 176-191 | 3,7,3',4'-tetrahydroxyflavone |
| Half-life (hr) ↗ | 0.5 | 2 |
| Typical dose (mg) ↗ | 0.3 | 500 |
| Dosing frequency | daily | pulsed 2 days/month (Mayo protocol) or daily continuous (empirical) |
| Routes | subcutaneous | oral |
| Onset (hr) | 1 | 1 |
| Peak (hr) | 2 | 4 |
| Molecular weight | 1815.17 | 286.24 |
| Molecular formula | C78H125N23O23S2 | C15H10O6 |
| Mechanism | Modified C-terminal fragment of human growth hormone proposed to stimulate beta-3 adrenergic receptor signaling in adipocytes, increasing lipolysis and fatty-acid oxidation without engaging the GH receptor or activating IGF-1. | Senolytic via Bcl-2 family inhibition (Bcl-xL, Bcl-w); broad polyphenol with Nrf2 activation, mTOR inhibition at high concentrations, and antioxidant effects. |
| Legal status | Not FDA approved; research-use-only grey market in most jurisdictions | OTC dietary supplement |
| WADA status | unknown | allowed |
| DEA / Rx | Not FDA approved; not scheduled; research-chemical status | OTC supplement |
| Pregnancy | Insufficient data; not recommended | Insufficient data |
| CAS | 221231-10-3 | 528-48-3 |
| PubChem CID | 71300630 | 5281614 |
| Wikidata | Q4654106 | Q230614 |
Safety profile
AOD-9604
Common side effects
- injection-site reactions
- transient mild headache (anecdotal)
- minimal in clinical trials
Contraindications
- pregnancy
- lactation
- no established human safety profile for chronic use
Interactions
- beta-blockers: theoretical antagonism of beta-3 adrenergic lipolytic signaling(minor)
Fisetin
Common side effects
- mild GI upset
- headache (rare)
Contraindications
- active cancer (theoretical, polyphenol interactions)
- pregnancy and lactation (insufficient data)
- concurrent CYP3A4-sensitive medications
Interactions
- statins (CYP3A4 substrates): theoretical reduction in statin clearance at high fisetin doses(minor)
- warfarin: theoretical CYP-mediated interaction; monitor INR if combining(moderate)
- other senolytics (rapamycin, dasatinib + quercetin): additive senolytic effect; pairing is investigational(minor)
Which Should You Take?
Fisetin comes out ahead for most readers on the criteria we weight: 2 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. AOD-9604 is the right call when one of the conditionals below applies.
- → If your priority is fat loss, pick AOD-9604.
- → If your priority is body composition, pick AOD-9604.
- → If your priority is healthspan extension, pick Fisetin.
- → If your priority is focus or working memory, pick Fisetin.
Edge case: If you want to avoid research-only / gray-market sourcing, Fisetin is the more accessible choice.
Default choice: Fisetin. Lower friction to source, and broader goal coverage. Reach for AOD-9604 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between AOD-9604 and Fisetin?
AOD-9604 and Fisetin differ in category (peptide vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, AOD-9604 or Fisetin?
AOD-9604 half-life is 0.5 hours; Fisetin half-life is 2 hours.
Can you stack AOD-9604 with Fisetin?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper